Clinical trials: Meningitis, Bacterial
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Tuberculosis, Extrapulmonary
Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).
Extrapulmonary TB (EPTB) accounts for nearly 30% of TB cases in HIV endemic settings, such as South Africa. The diagnosis of extrapulmonary TB is complicated by the poor performance of Gene Xpert and TB Culture in extrapulmonary…
- Trial name
- Epi-TB (NCT06135818)
- Testing
- IRISA-TB
- Where
- 4 sites in South Africa, Zambia and 1 more
- Volunteers
- 2,160 people
- Sponsor
- University of Cape Town
Tuberculous Meningitis
Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients.
- Trial name
- NCT03898635
- Testing
- Linezolid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Huashan Hospital
Urinary Tract Infections, Meningitis
Febrile Infant Diagnostic Assessment and Outcome Study
Febrile infants under 3 months of age represent a high risk group for invasive bacterial infection (IBI) and UTI with approximately 10-20% having bacteremia, meningitis or urinary tract infection.
- Conditions
- Urinary Tract Infections, Meningitis, Sepsis, Bacterial Infections
- Trial name
- FIDO (NCT05259683)
- Where
- United Kingdom
- Volunteers
- 2,076 people
- Sponsor
- Queen's University, Belfast
Meningitis, Meningococcal Infection
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation
The purpose of this study is to assess the immunogenicity and safety of Menactra® vaccine given as a two-dose series in infants and toddlers.
- Trial name
- NCT01890759
- Testing
- Meningococcal Diphtheria Toxoid Vaccine
- Where
- 8 sites in India, Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Cryptococcal, HIV Infections
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
To compare the safety and effectiveness of fluconazole with that of placebo as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002294
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Cryptococcal Meningitis, HIV Infections
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans.
- Trial name
- NCT00885703
- Testing
- Fluconazole, Amphotericin B
- Where
- 10 sites in United States, India and 6 more
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningococcal Meningitis
Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine
Primary objective: To assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.
- Trial name
- ETH-TVT (NCT00994695)
- Testing
- Mencevax ACW Vaccine
- Where
- Ethiopia
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Armauer Hansen Research Institute, Ethiopia
Meningitis, Cryptococcal, HIV Infections
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002077
- Testing
- Fluconazole
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Meningitis, Cryptococcal, HIV Infections
Dexamethasone in Cryptococcal Meningitis
To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension.
- Trial name
- NCT00000776
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryptococcal Infection, Cryptococcal Pneumonia
Fungal Infection Susceptibility
The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and the following United States Code of…
- Conditions
- Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis, Cryptococcal Meningitis
- Trial name
- NCT00001352
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Meningococcal Meningitis
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
The purpose of the study was to evaluate the immunogenicity and safety profile of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when given alone compared to…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT03205358
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
- Where
- 8 sites in Finland
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Meningitis
Comparison of Two Meningococcal ACWY Conjugate Vaccines
There is evidence of waning immunity in individuals vaccinated against meningitis C as part of the UK infant immunisation schedule.
- Trial name
- PRIME (NCT01192997)
- Testing
- Menveo, MenACWY-TT
- Where
- 3 sites in United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Public Health England
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years.
- Trial name
- NCT07505888
- Testing
- experimental vaccine, active comparator vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Tuberculosis, Meningeal, Linezolid
Pharmacokinetic Study of Linezolid for TB Meningitis
Tuberculosis meningitis (TBM) is the most severe manifestation of TB, resulting in death or neurological disability in up to 50% of affected patients, despite antibacterial treatment.
- Trial name
- SIMPLE (NCT03537495)
- Testing
- Linezolid
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Universitas Padjadjaran
Meningitis, Cryptococcal, HIV Infections
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the…
- Trial name
- NCT00000639
- Testing
- Itraconazole, Flucytosine, Fluconazole
- Where
- 24 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryptococcal Meningitis, HIV
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
The aim of the trial is to demonstrate that in a sub-Saharan African setting, the association of: 1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100 mg/kg/j) as induction therapy 2.
- Trial name
- Flucocrypto (NCT01715922)
- Testing
- Fluconazole, Flucytosine, lumbar punctures
- Where
- 7 sites in Burundi, Côte d’Ivoire
- Volunteers
- 41 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Pneumococcal Disease
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to…
- Trial name
- NCT00757575
- Where
- 2 sites in Japan
- Volunteers
- 28,511 people
- Sponsor
- Pfizer
Meningitis, Meningococcal
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.
- Trial name
- NCT00808028
- Testing
- meningococcal B rLP2086 vaccine.
- Where
- 27 sites in Australia, Poland and 1 more
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningitis, Meningococcal Meningitis
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
The aim of this study is to provide information on the persistence of bactericidal antibodies following Menactra booster vaccination in study MTA77 ( NCT01442675).
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02633787
- Testing
- Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 4 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company